Recurrent Multiple Evanescent White Dot Syndrome (MEWDS) Following First Dose and Booster of the mRNA-1273 COVID-19 Vaccine: Case Report and Review of Literature
Abstract
:1. Introduction
2. Case Report
3. Discussion
Authors | Age | Sex | Race | Vaccine | Dose | Time from Vaccine to Symptoms (Days) | Ocular Symptoms | Past History | Course | Initial VA | Final VA | Treatment | Resolution |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bolletta et al. [26] | 53 | M | _ | Pfizer BNT162b2 | 2nd | 28 | Decreased VA, scotoma, | None | Acute | 20/25 | 20/20 | Observation | Complete resolution |
18 | F | _ | Pfizer BNT162b2 | 1st | 4 | Blurred vision, visual field defect | None | Acute | 20/66 | 20/20 | Observation | Complete resolution | |
48 | M | _ | Pfizer BNT162b2 | 1st | 7 | Decreased VA | None | Acute | 20/400 | 20/20 | Observation | Complete resolution | |
Xu et al. [13] | 49 | F | _ | Sinovac- CoronaVAC vaccine (Inactivated) | 1st | 2 | Blurred vision | MEWDS | Recurrent | 20/100 | 20/20 | Tapered prednisone, starting with 20 mg | Complete resolution |
Lin et al. [27] | 36 | F | Taiwanese | Medigen Vaccine Biologics Corporation (MVC) COVID-19 Vaccine | 1st | 2 | Photopsia | High myopia (−9.75D/−7.5D) | Acute | 20/25 | 20/20 | observation | Complete resolution in 4 weeks |
Smith et al. [28] | 15 | M | _ | Pfizer BNT162b2 | 2nd | 14 | Blurred vision, myodesopsia, photopsia | None | Acute | 20/100 | 20/20 | Tapered oral prednisone, starting at 40 mg | Complete resolution in 2 weeks |
21 | F | _ | Pfizer BNT162b2 | 2nd | 21 | Blurred vision | None | Acute | 20/60 | 20/20 | Tapered oral prednisone, starting at 40 mg | Complete resolution in 2 weeks | |
Yasuda et al. [29] | 67 | F | Japanese | Pfizer BNT162b2 | 2nd | 1 | Scotoma, photopsia, blurred vision | None | Acute | 20/100 | 20/25 | _ | Patient also developed moderate vitritis, almost complete resolution at 2 weeks. |
Inagawa et al. [30] | 30 | F | Japanese | Pfizer BNT162b2 | 1st, 2nd | 7 and 3, respectively | Blurred vision | None | Recurrent | 20/20 OU | 20/30 | Topical 0.1% fluorometholone for 21 days | Both eyes had fundus abnormalities L>R |
Tomishige et al. [31] | 38 | F | White | Sinovac- CoronaVac vaccine (Inactivated) | 1st | 7 | Photopsia, decreased VA | None | Acute | 20/400 | 20/20 | Tapered oral prednisone, starting at 80 mg oral prednisone | Complete resolution in 4 weeks |
Rabinovitch et al. [32] | 28 | F | _ | Pfizer BNT162b2 | 2nd | 0 | Blurred vision, scotoma, photopsia | None | Acute | _ | _ | _ | Significant improvement on FU |
39 | M | _ | Pfizer BNT162b2 | 2nd | _ | Blurred vision, scotoma, photopsia | None | Acute | _ | _ | _ | Significant improvement on FU | |
Alhabshan et al. [33] | 71 | F | White | Moderna mRNA-1273 | 1st booster | 3 | Blurred vision and scotoma | Myopic and retinal tear | Acute | 20/30 | _ | _ | Spontaneous improvement |
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Jampol, L.M.; Sieving, P.A.; Pugh, D.; Fishman, G.A.; Gilbert, H. Multiple evanescent white dot syndrome. I. Clinical findings. Arch. Ophthalmol. 1984, 102, 671–674. [Google Scholar] [CrossRef] [PubMed]
- Papasavvas, I.; Mantovani, A.; Tugal-Tutkun, I.; Herbort, C.P. Multiple evanescent white dot syndrome (MEWDS): Update on practical appraisal, diagnosis and clinicopathology; a review and an alternative comprehensive perspective. J. Ophthalmic Inflamm. Infect. 2021, 11, 45. [Google Scholar] [CrossRef] [PubMed]
- Testi, I.; Brandão-de-Resende, C.; Agrawal, R.; Pavesio, C. Ocular inflammatory events following COVID-19 vaccination: A multinational case series. J. Ophthalmic Inflamm. Infect. 2022, 12, 4. [Google Scholar] [CrossRef]
- Watson, O.J.; Barnsley, G.; Toor, J.; Hogan, A.B.; Winskill, P.; Ghani, A.C. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect. Dis. 2022, 22, 1293–1302. [Google Scholar] [CrossRef]
- Sharif, N.; Alzahrani, K.J.; Ahmed, S.N.; Dey, S.K. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front. Immunol. 2021, 12, 714170. [Google Scholar] [CrossRef]
- WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int (accessed on 10 September 2022).
- Rosenblum, H.G.; Hadler, S.C.; Moulia, D.; Shimabukuro, T.T.; Su, J.R.; Tepper, N.K.; Ess, K.C.; Woo, E.J.; Mba-Jonas, A.; Alimchandani, M.; et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices—United States, July 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1094–1099. [Google Scholar] [CrossRef]
- Ramakrishnan, M.S.; Patel, A.P.; Melles, R.; Vora, R.A. Multiple Evanescent White Dot Syndrome: Findings from a Large Northern California Cohort. Ophthalmol. Retina. 2021, 5, 850–854. [Google Scholar] [CrossRef] [PubMed]
- Bosello, F.; Westcott, M.; Casalino, G.; Agorogiannis, G.; Micciolo, R.; Rees, A.; Pavesio, C. Multiple evanescent white dot syndrome: Clinical course and factors influencing visual acuity recovery. Br. J. Ophthalmol. 2022, 106, 121–127. [Google Scholar] [CrossRef]
- WHO. Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification, 2nd ed.; 2019 Update; WHO: Geneva, Switzerland, 2019; Available online: https://www.who.int/publications-detail-redirect/9789241516990 (accessed on 25 September 2022).
- Ng, C.C.; Jumper, J.M.; Cunningham, E.T. Multiple evanescent white dot syndrome following influenza immunization—A multimodal imaging study. Am. J. Ophthalmol. Case Rep. 2020, 19, 100845. [Google Scholar] [CrossRef]
- COVID Vaccinations Administered Number by Manufacturer U.S. 2022. Statista. Available online: https://www.statista.com/statistics/1198516/covid-19-vaccinations-administered-us-by-company/ (accessed on 10 September 2022).
- Chen, Y.; Xu, Z.; Wang, P.; Li, X.M.; Shuai, Z.W.; Ye, D.Q.; Pan, H.F. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022, 165, 386–401. [Google Scholar] [CrossRef]
- Yadav, T.; Srivastava, N.; Mishra, G.; Dhama, K.; Kumar, S.; Puri, B.; Saxena, S.K. Recombinant vaccines for COVID-19. Hum. Vaccines Immunother. 2020, 16, 2905–2912. [Google Scholar] [CrossRef]
- Maleki, A.; Look-Why, S.; Manhapra, A.; Foster, C.S. COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence? J. Ophthalmic Vis. Res. 2021, 16, 490–501. [Google Scholar] [CrossRef] [PubMed]
- Ngo, S.T.; Steyn, F.J.; McCombe, P.A. Gender differences in autoimmune disease. Front. Neuroendocrinol. 2014, 35, 347–369. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choubey, D.; Moudgil, K.D. Interferons in Autoimmune and Inflammatory Diseases: Regulation and Roles. J. Interferon Cytokine Res. 2011, 31, 857–865. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vojdani, A.; Kharrazian, D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin. Immunol. Orlando Fla. 2020, 217, 108480. [Google Scholar] [CrossRef]
- Sawant, O.B.; Wright, S.S.E.; Jones, K.M.; Titus, M.S.; Dennis, E.; Hicks, E.; Majmudar, P.A.; Kumar, A.; Mian, S.I. Prevalence of SARS-CoV-2 in human post-mortem ocular tissues. Ocul. Surf. 2021, 19, 322–329. [Google Scholar] [CrossRef]
- Bragazzi, N.L.; Hejly, A.; Watad, A.; Adawi, M.; Amital, H.; Shoenfeld, Y. ASIA syndrome and endocrine autoimmune disorders. Best Pract. Res. Clin. Endocrinol. Metab. 2020, 34, 101412. [Google Scholar] [CrossRef]
- Rabinovitch, T.; Ben-Arie-Weintrob, Y.; Hareuveni-Blum, T.; Shaer, B.; Vishnevskia-Dai, V.; Shulman, S.; Newman, H.; Biadsy, M.; Masarwa, D.; Fischer, N.; et al. Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 Infection: A Possible Association. Retina Phila Pa 2021, 41, 2462–2471. [Google Scholar] [CrossRef]
- Haseeb, A.A.; Solyman, O.; Abushanab, M.M.; Abo Obaia, A.S.; Elhusseiny, A.M. Ocular Complications Following Vaccination for COVID-19: A One-Year Retrospective. Vaccines 2022, 10, 342. [Google Scholar] [CrossRef]
- Elnahry, A.G.; Asal, Z.B.; Shaikh, N.; Dennett, K.; Elmohsen, M.N.A.; Elnahry, G.A.; Shehab, A.; Vytopil, M.; Ghaffari, L.; Athappilly, G.K.; et al. Optic neuropathy after COVID-19 vaccination: A report of two cases. Int. J. Neurosci. 2021, 1–7. [Google Scholar] [CrossRef]
- Nioi, M.; d’Aloja, E.; Fossarello, M.; Napoli, P.E. Dual Corneal-Graft Rejection after mRNA Vaccine (BNT162b2) for COVID-19 during the First Six Months of Follow-Up: Case Report, State of the Art and Ethical Concerns. Vaccines 2021, 9, 1274. [Google Scholar] [CrossRef] [PubMed]
- Jin, S.X.; Juthani, V.V. Acute Corneal Endothelial Graft Rejection With Coinciding COVID-19 Infection. Cornea 2021, 40, 123–124. [Google Scholar] [CrossRef] [PubMed]
- Bolletta, E.; Iannetta, D.; Mastrofilippo, V.; Simone, L.D.; Gozzi, F.; Croci, S.; Bonacini, M.; Belloni, L.; Zerbini, A.; Adani, C.; et al. Uveitis and Other Ocular Complications Following COVID-19 Vaccination. J. Clin. Med. 2021, 10, 5960. [Google Scholar] [CrossRef] [PubMed]
- Multiple Evanescent White Dot Syndrome Following Medigen Vaccine Biologics Corporation COVID-19 Vaccination—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/35442848/ (accessed on 19 July 2022).
- Multiple Evanescent White Dot Syndrome following COVID-19 mRNA Vaccination in Two Patients—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/35201960/ (accessed on 19 July 2022).
- Yasuda, E.; Matsumiya, W.; Maeda, Y.; Kusuhara, S.; Nguyen, Q.D.; Nakamura, M.; Hara, R. Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination. Am. J. Ophthalmol. Case Rep. 2022, 26, 101532. [Google Scholar] [CrossRef] [PubMed]
- Inagawa, S.; Onda, M.; Miyase, T.; Murase, S.; Murase, H.; Mochizuki, K.; Sakaguchi, H. Multiple evanescent white dot syndrome following vaccination for COVID-19: A case report. Medicine 2022, 101, e28582. [Google Scholar] [CrossRef]
- Tomishige, K.S.; Novais, E.A.; Finamor, L.P.D.S.; Nascimento, H.M.d.; Belfort, R. Multiple evanescent white dot syndrome (MEWDS) following inactivated COVID-19 vaccination (Sinovac-CoronaVac). Arq. Bras. Oftalmol. 2022, 85, 186–189. [Google Scholar] [CrossRef]
- Uveitis after the BNT162b2 mRNA Vaccination against SARS-CoV-2 Infection: A Possible Association—PubMed. Available online: https://pubmed.ncbi.nlm.nih.gov/34369440/ (accessed on 19 July 2022).
- Alhabshan, R.; Scales, D. Multiple Evanescent White Dot Syndrome Developing Three Days following Administration of mRNA-1273 Booster Vaccine: Case Report. Case Rep. Ophthalmol. 2022, 13, 570–577. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Soifer, M.; Nguyen, N.V.; Leite, R.; Fernandes, J.; Kodati, S. Recurrent Multiple Evanescent White Dot Syndrome (MEWDS) Following First Dose and Booster of the mRNA-1273 COVID-19 Vaccine: Case Report and Review of Literature. Vaccines 2022, 10, 1776. https://doi.org/10.3390/vaccines10111776
Soifer M, Nguyen NV, Leite R, Fernandes J, Kodati S. Recurrent Multiple Evanescent White Dot Syndrome (MEWDS) Following First Dose and Booster of the mRNA-1273 COVID-19 Vaccine: Case Report and Review of Literature. Vaccines. 2022; 10(11):1776. https://doi.org/10.3390/vaccines10111776
Chicago/Turabian StyleSoifer, Matias, Nam V. Nguyen, Ryan Leite, Josh Fernandes, and Shilpa Kodati. 2022. "Recurrent Multiple Evanescent White Dot Syndrome (MEWDS) Following First Dose and Booster of the mRNA-1273 COVID-19 Vaccine: Case Report and Review of Literature" Vaccines 10, no. 11: 1776. https://doi.org/10.3390/vaccines10111776
APA StyleSoifer, M., Nguyen, N. V., Leite, R., Fernandes, J., & Kodati, S. (2022). Recurrent Multiple Evanescent White Dot Syndrome (MEWDS) Following First Dose and Booster of the mRNA-1273 COVID-19 Vaccine: Case Report and Review of Literature. Vaccines, 10(11), 1776. https://doi.org/10.3390/vaccines10111776